Premium
Cl‐IB‐MECA inhibits human erythropoiesis
Author(s) -
Bhanu Natarajan V.,
Aerbajinai Wulin,
Gantt Nicole M.,
Jackson Edwin K.,
Goh SungHo,
Terry Lee Y.,
Miller Jeffery L.
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06540.x
Subject(s) - erythropoiesis , erythroblast , chemistry , microbiology and biotechnology , pharmacology , biology , cancer research , medicine , anemia
Summary Candidate drugs are being sought for the suppression of human erythropoiesis. Cl‐IB‐MECA [2‐chloro‐ N 6‐(3‐iodobenzyl)‐adenosine‐5′‐ N ‐methyluronamide] is a derivative of adenosine that inhibits the growth of leukaemic cell lines. To determine the effects of Cl‐IB‐MECA upon erythropoiesis, studies were performed by using an ex vivo culture system of primary human CD34+ cells. Cl‐IB‐MECA suppressed erythroblast growth and maturation at doses ≥50 μ mol/l through a mechanism of cell cycle inhibition and accumulation of cells in the G1/G0 phase. These findings demonstrate that Cl‐IB‐MECA inhibits human erythropoiesis, and suggest that further consideration of this drug is warranted for patients with erythrocytosis or polycythemia syndromes.